Technology Focus

Nanoparticles offer a cutting-edge approach to targeted drug delivery, significantly improving bioavailability. By precisely delivering therapeutic agents directly to the intended site, these nanoparticles enhance the effectiveness of treatments while minimizing side effects. This targeted delivery system ensures that drugs reach their full potential, providing a more efficient and patient-friendly solution to various medical challenges.

SiNON Nano Sciences Focus on High-Risk Lung Cancers

Comparison of Lung Cancer & Non Small Cell Lung Cancer

Lung cancer(Total) Estimated % of New cases

14%

Non Small cell Lung Cancer(NSCLC) Estimated % of New cases

85%

High Risk Lung cancer

Based on Brain Metastasis Risk we focus on High-Risk Lung cancer

Comparison of Brain Metastasis Risk and Contribution Across Cancer Types

Focus on NSCLC and Breast cancer in Brain Metastasis Research

Non-Small Cell Lung Cancer (NSCLC) and breast cancer are two of the most frequently diagnosed cancers, each carrying a relatively high risk of brain metastasis compared to other cancer types. Given their prevalence, they are particularly relevant to a significant portion of the population. Our Pharmaceutics and Efficacy study in animal models will concentrate on cancers that have both a high percentage of new cases and a significant contribution to brain metastasis, with a primary focus on NSCLC.

Targeted Research: Concentrating on cancers with the highest risk of brain metastasis.
NSCLC Focus: Prioritizing Non-Small Cell Lung Cancer due to its significant impact on brain metastasis.
Relevance: Addressing cancers that affect a large portion of the population.

Cancer Type	Estimated % of New cases	Brain Metastasis Risk	Estimated % contribution to brain Metastasis Cases
Breast Cancer	12-15%	5-20%	0.6 - 3.0%
Lung Cancer(Total)	13-14%	Up to 40%	2.6 - 5.6%
Non Small Cell Lung Cancer (NSCLC)	80-85% of Lung Cancer Cases	10-30%	2.0 - 4.2% (subset of lung cancer)
Colorectal Cancer	8-10%	1-4%	0.08 - 0.4%
Head and Neck Cancers	3-4%	1-5%	0.03 - 0.2%
Liver Cancer	2-3%	Up to 15%	0.3 - 0.45%
Pancreatic Cancer	2-3%	Up to 30%	0.6 - 0.9%